Used in research as a selective antagonist for the neurotensin receptor NTS1, SPM 907 helps investigate the role of neurotensin signaling in pain modulation, schizophrenia, and drug addiction. It is valued in preclinical studies for its ability to cross the blood-brain barrier, enabling central nervous system effects in animal models. Its application supports the development of targeted therapies for neurological and psychiatric disorders.